Fig. 4.

Comparisons of Selinexor and Trametinib effectiveness depending on KRAS codon and TP53 alterations. (A, B) Predicted weekly change in growth rates for treatment compared to vehicle, where vehicle was normalized to equal a weekly growth rate of 1. Results are from a log linear mixed effects model testing the interaction between treatment, weekly growth rate, and KRAS codon or TP53 mutation [39]. (A) Comparison of predicted weekly growth rates after treatment with either Selinexor or Trametinib depending on presence of G12C (n = 4) or G12D (n = 3) codon alterations. There was no significant difference for either Selinexor (p = 0.15) or Trametinib (p = 0.52). (B) Comparison of predicted weekly growth rates after treatment with either Selinexor or Trametinib depending on TP53^WT (n = 6) or TP53^mut (n = 4) status. Predicted weekly change in growth rates for treatment compared to vehicle, where vehicle was normalized to equal a weekly growth rate of 1. There was no significant difference in the effect of Trametinib (p = 0.34), but Selinexor decreased the rate of growth significantly more in TP53^WT compared to TP53^mut models (p = 0.04).